Major depressive disorder (MDD) is one of the most prevalent mental health disorders and has a significant societal economic burden. Antidepressants and cognitive behavioral therapy are two primary interventions for the standardized treatment of MDD. However, their weaknesses, such as a low response rate, a high risk of adverse events from medication, and the high cost of cognitive behavioral therapy, have resulted in a need for complementary and alternative medicine (CAM). Among the various therapeutic interventions in CAM, electroacupuncture and moxibustion have been widely used to treat various mental illnesses, including MDD. The aim of this study is to evaluate the feasibility of conducting a full-scale randomized controlled trial to investigate the efficacy and safety of electroacupuncture plus moxibustion therapy for MDD. We will include patients between the ages of 19 to 65 years with MDD. A total of 30 participants will be recruited, and they will be randomly allocated into two groups at a 1:1 ratio. Patients in the treatment and control groups will, respectively, receive real and sham electroacupuncture/moxibustion treatments, for a total of 20 sessions over 8 weeks. The primary outcome will be the Hamilton Rating Scale for Depression, and the secondary outcomes will be Beck’s Depression Inventory, the Insomnia Severity Index, the State-Trait Anxiety Inventory, the EuroQol 5-Dimension Index, the Measure Yourself Medical Outcome Profile version 2, and electroencephalography. Adverse events will be monitored at each visit to assess safety. All outcomes will be assessed and analyzed by researchers blinded to the treatment allocation. This is a two-armed, parallel-design, patient-assessor blinded, multicenter, randomized, sham-controlled pilot clinical trial. Data will be analyzed before and after treatment and during a 4-week follow-up. The results of the trial will provide a basis for further studies assessing the efficacy and safety of electroacupuncture plus moxibustion treatment for MDD. Korean Clinical Trial Registry, CRIS-KCT0001810 . Registered on 5 February 2016 (retrospectively registered; date of enrollment of the first participant to the trial: 2 December 2015).

The first treatment option for major depressive disorder (MDD) is antidepressants, however, there is substantial demand for alternative therapies due to its low compliance and remission rates. This study was aimed to explore the effectiveness, safety, and feasibility of electroacupuncture plus moxibustion therapy for MDD. Thirty adults with MDD were randomly assigned to the treatment group (TG) or control group (CG). The TG was treated with electroacupuncture plus moxibustion, and the CG received sham interventions at non-acupoints for 8 weeks. The primary outcome measure was the intergroup difference of the mean change of total score of the Hamilton rating scale for depression (HRSD) between baseline and week 9. Secondary outcome measures were Beck's depression inventory, insomnia severity index, the state-trait anxiety inventory, the EuroQol-5 dimension index, the measure yourself medical outcome profile version 2, and frontal alpha asymmetry measured by electroencephalography. Adverse events (AEs) were monitored for safety assessment. The primary outcome measure was not significantly different between the two groups (p=0.2641), although the scores of HRSD in both groups improved significantly after treatment. No significant difference was identified between groups in secondary outcome measures. The incidence of AE was not significantly different between the two groups (p=0.1067). A clinical trial using electroacupuncture plus moxibustion for MDD seems feasible. However, further studies with the larger size, adopting ideal controls are warranted to provide a confirmative conclusion to the efficacy and safety of electroacupuncture plus moxibustion for MDD.

Objectives: To evaluate the efficacy and safety of tamsulosin and Hachimijiogan or Ryutanshakanto in patients with lower urinary tract symptoms due to benign prostatic hyperplasia.Methods: A prospective, randomized, double‐blind method was used to determine the efficacy and safety of the combination or placebo at baseline and 4, 8, and 12 weeks of study. The International Prostate Symptom Score, quality of life index, complete voiding diary, and National Institutes of Health‐Chronic Prostatitis Symptom Index were studied. Uroflowmetery and postvoid residual urine volume were measured and compared. Laboratory tests including prostate‐specific antigen were performed.Results: In all groups, International Prostate Symptom Score and quality of life showed improvement, but no significant differences were shown among the groups. Prostate volume increased after treatment, and uroflowmetric parameters showed improvements after treatment without significance among the three groups. The total score of the National Institutes of Health‐Chronic Prostatitis Symptom Index showed a significant improvement in all groups, without significant differences among the groups. Only the pain sub‐score of the National Institutes of Health‐Chronic Prostatitis Symptom Index showed a significant decrease in the tamsulosin with Ryutanshakanto group compared to the control group. A total of 11 adverse reactions occurred, but they were mild and not related to the study drugs.Conclusion: Ryutanshakanto can provide pain relief in patients with chronic prostatitis and chronic pelvic pain syndrome. If more research is conducted, Hachimijiogan and Ryutanshakanto may be applied as add‐on treatments in patients with storage symptoms with alpha‐blocker monotherapy.

Insomnia is a common sleep disorder that affects many adults either transiently or chronically. The societal cost of insomnia is on the rise, while long-term use of current drug treatments can involve adverse effects. Recently, electroacupuncture (EA) has been used to treat various conditions including insomnia. The objective of this study is to provide scientific evidence for the effect and safety of using EA to treat insomnia. In this multicentre, assessor-blind, three-arm, parallel-design, randomised controlled trial, 150 participants will be assigned to the EA group, the sham EA (SEA) group, or the usual care group. The EA and SEA groups will receive the specific treatments 2–3 times a week for 4 weeks, for a total of 10 sessions, whereas the usual care group will not receive EA and will continue with usual care during the same time period. The primary outcome measure will be changes in the Insomnia Severity Index 5 weeks after randomisation. The secondary outcomes will include the Pittsburgh Sleep Quality Index, the Hospital Anxiety and Depression Scale, a sleep diary, the EuroQoL-5 dimension questionnaire, the levels of melatonin and cortisol, and the Patient Global Impression of Change. Safety will be assessed at each visit. The results of this multicentre randomised controlled trial will contribute to provide rigorous clinical evidence for the effects and safety of EA for insomnia disorder. Korean Clinical Trial Registry, CRIS, KCT0001685 . Registered on 2 November 2015 (retrospectively registered). Date of enrolment of the first participant to the trial 13 October 2015.

Purpose: Pain and symptoms associated with dysmenorrhea and premenstrual syndrome (PMS) significantly impact the quality of life of women of reproductive age, potentially leading to various physical and psychological health problems that negatively influence daily activities. This systematic review aimed to evaluate the effectiveness of digital healthcare interventions in reducing health issues related to dysmenorrhea and PMS in women of reproductive age.Methods: We conducted a comprehensive systematic literature search of three databases (PubMed, Web of Science, and the Cochrane Library) up to August 2024 to identify randomized controlled trials evaluating digital health interventions for managing dysmenorrhea and PMS symptoms in reproductive-age women. Of the 750 articles initially identified, eight studies fulfilled the inclusion criteria. Two independent reviewers assessed the methodological quality of the included studies using the Cochrane Risk of Bias tool.Results: Eight studies were included, categorized as smartphone application-based interventions (n=5) and web-based programs (n=3). Digital healthcare interventions effectively reduced dysmenorrhea-related pain and positively impacted symptom management for both dysmenorrhea and PMS. PMS symptom severity was the most frequently measured outcome used to evaluate intervention effectiveness. These findings emphasize the potential of mobile and web-based platforms as accessible and effective tools for managing menstrual symptoms among women.Conclusion: This review highlights the importance of digital healthcare in reducing health issues related to menstrual symptom management. It also highlights the critical role of nursing in integrating digital healthcare solutions to support menstrual health management among reproductive-age women.

Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author). Background: Mobile health (mHealth) is a major source of health management systems such as health promotion behavior, chronic disease, and mental illness. Moreover, mHealth, a new model of digital healthcare in need of change due to the COVID-19 pandemic, will increase and demand for use worldwide. Accordingly, interest in health care in everyday life and the importance of mobile health are growing. Objective: We developed a MibyeongBogam (MBBG) application that evaluates the user’s subhealth status by use of a smartphone and provides a health management method based on that user’s subhealth status for use in everyday life. The primary objective of this study was to compare health status awareness after the use of the MBBG application between the intervention and control groups, and to evaluate the application’s practicality. Methods: This study was a prospective, open-label, parallel group, randomized controlled trial as an intervention for MBBG. The study was conducted at two hospitals in Korea with 150 healthy people in their 30s and 40s, at a 1:1 allocation ratio. Participants visited the hospital three times: pre-intervention, intermediate visit six weeks after intervention, and final visit 12 weeks after intervention. Key endpoints were measured at the first visit before intervention and at 12 weeks after intervention. The primary outcome was the awareness of subhealth status and secondary outcomes were health status, health-promoting behaviors, and motivation for healthy behaviors. Results: The primary outcome, subhealth awareness, tended to slightly increase in both groups after the uncompensated intervention, but there was no significant difference between groups (MBBG group = 23.69±0.25, control group = 23.1±0.25, p=0.088). In the case of secondary outcomes, only some variables of subhealth status showed significant differences between the two groups after intervention, and the intervention group showed an improvement in the total score of subhealth (p = 0.025), sleep disturbance (p = 0.024), depression (p = 0.003), anger (p = 0.01), and anxiety symptoms (p = 0.009) compared to the control group. Conclusions: In this study, the MBBG application showed positive potential for improving the health, especially the mental health, of individuals without particular health problems. However, the effects of the application on health-promoting behaviors were not clearly evaluated. Therefore, further studies to assess improvements in health after the use of personalized health management programs provided by the MBBG application would need to be performed. It is thought that the MBBG application would be useful for the general public, who are not diagnosed with a disease but cannot enjoy an optimal daily life due to discomfort, to seek strategies that can improve their health. Clinical Trial: Clinical Research Information Service, KCT0003488. (https://cris.nih.go.kr/cris/search/search_result_st01.jsp?seq=14379)